Positron emision tomography with18F-fluorodeoxyglucose in patients with uterine sarcoma;Tomografía por emisión de positrones con18F- fluordesoxiglucosa en pacientes con sarcoma uterino

Revista Espanola de Medicina Nuclear

Volumn 26, Issue 4, 2007, Pages 189-195

  Rebollo Aguirre, A Custodio ^a   Ramos Font, C ^a   Bellon Guardia M E ^a   Cabello Garcia D ^a   Gallego Peinado, M ^a   Rodriguez Fernandez A ^a   Llamas Elvira, J M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

FDG PET; Follow up; Recurrence; Staging; Uterine cancer; Uterine sarcoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOSARCOMA; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; LEIOMYOSARCOMA; LUNG METASTASIS; POSITRON EMISSION TOMOGRAPHY; TUMOR RECURRENCE; UTERUS SARCOMA;

EID: 34547744984     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1157/13107970     Document Type: Article

References (37)

1. Pérez CA, Grisby PW, Mutch DG, Chao KSC, Basil J. Gynecologic tumors. In: Rubin P, Williams JP, editors. Clinical oncology. A multidisciplinary approach for physicians and students. 8th edition. Philadelphia: WB Saunders Company; 2001. p. 462-521.
2. Burke TW, Mundt AJ, Muggia FM. Cancers of the uterine body. In: De Vita V, Hellman S, Rosenberg SA, editors. Cancer. Principles & Practice. 7th edition. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1341-60.
3. Yen TC, Lai CH. Positron emission tomography in gynecologic cancer. Semin Nucl Med. 2006;36:93-104.
4. Belhocine TZ, Grisby PW. FDG PET and PET-CT in uterine cancers. Cancer Therapy. 2005;3:201-18.
5. Pandit-Taskar N. Oncologic imaging in gynecologic malignancies. J Nucl Med. 2005;46:1842-50.
6. Grahek D, Barranger E, Daraï E, Uzan S, Talbot JN. Intérêt de la tomographie par émission de positrons au [18F]-fluorodéoxyglucose dans le diagnostic, le bilan d'extension et la recherche de récidive des cancers gynécologiques et mammaires. Gynécol Obstét Fértil. 2005;33:371-81.
7. Suárez Fernández JP, Domínguez Grande ML, Maldonado Suárez A, García Bernardo L, Pozo García MA, Alfonso Alfonso JM. Aportación de la Tomografía por Emisión de Positrones (PET) al manejo de los tumores malignos de ovario y útero. Oncología (Barc). 2005;28:218-31.
8. Khan N, Oriuchi N, Yoshizaki A, Kanuma T, Higuchi T, Endo K. Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer. Ann Nucl Med. 2005;19:137-45.
9. Kumar R, Alavi A. PET imaging in gynecologic malignancies. Radiol Clin North Am. 2004;42:1155-67.
10. Jadvar H, Conti PS. The reproductive tract. Semin Nucl Med. 2004;34:262-73.
11. Grisaru D, Almog B, Levine C, Metser U, Fishman A, Lerman H, et al. The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies. Gynecol Oncol. 2004;94:680-4.
12. Huglo D, Vinater D. Apport de la tomographie d'émission de positrons au [18F]-fluoro-désoxy-glucose en cancérologie gynécologique et mammaire. Gynécol Obstét Fértil. 2004;32:330-9.
13. FNCLCC. Recommandations pour la pratique clinique: mise à jour 2003 des standards, options et recommandations pour l'utilisation de la TEP-FDG dans la prise en charge des cancers gynécologiques et cancers du sein. Gynécol Obstét Fértil. 2004;32:352-71.
14. Umesaki N, Tanaka T, Miyama M, Kawamura N, Ogita S, Kawabe J, et al. Positron emission tomography with 18F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power doppler imaging. Gynecol Oncol. 2001;80:372-7.
15. Murakami M, Tsukada H, Shida M, Watanabe M, Maeda H, Koido S, et al. Whole-body positron emission tomography with F-18 fluorodeoxyglucose for detection of recurrence in uterine sarcomas. Int J Gynecol Cancer. 2006;16:854-60.
16. Jadvar H, Fischman AJ. Evaluation of rare tumors with [F-18]fluorodeoxyglucose positron emission tomography. Clin Positron Imaging. 1999;2:153-8.
17. Umesaki N, Tanaka T, Miyama M, Ogita S, Kawabe J, Okamura T, et al. Positron emission tomography using 2-[(18)F] fluoro-2-deoxy-D-glucose in the diagnosis of uterine leiomyosarcoma: a case report. Clin Imaging. 2001;25:203-5.
18. Chander S, Ergun EL. Positron emission tomographic-computed tomographic imaging of a uterine sarcoma. Clin Nucl Med. 2003;28:443-4.
19. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70:209-62.
20. 18F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med. 2002;29:1132-9.
21. Saga T, Higashi T, Ishimori T, Mamede M, Nakamoto Y, Mukai T, et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med. 2003;17:197-203.
22. 18F-FDG PET in the management of endometrial cancer. Eur J Nucl Med Mol Imaging. 2006;33:36-44.
23. Torizuka T, Nakamura F, Takekuma M, Kanno T, Ogusu T, Yoshikawa E, et al. FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. Nucl Med Commun. 2006;27:481-7.
24. Horowitz NS, Dehdashti F, Herzog TJ, Rader JS, Powell MA, Gibb RK, et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastases in uterine corpus cancer. Gynecol Oncol. 2004;95:546-51.
25. 18FDG. Madrid: Agencia de Evaluación de Tecnologías Sanitarias - Instituto de Salud Carlos III - Ministerio de Sanidad y Consumo, 2005.
26. Subhas N, Patel PV, Pannu HK, Jacene HA, Fishman EK, Wahl R. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics. 2005;25:1031-43.
27. Gorospe L, Raman S, Echeveste J, Avril N, Herrero Y, Hernández S. Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients. Nucl Med Commun. 2005;26:671-87.
28. 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med. 2004;45:266-71.
29. Yasuda S, Ide M, Takagi S, Shohtsu A. Intrauterine accumulation of F-18 FDG during menstruation. Clin Nucl Med. 1997;22:793-4.
30. Chander S, Meltzer CC, McCook BM. Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography. Clin Nucl Med. 2002;27:22-4.
31. Villar Luque LM, Sau Llanas P, Cantero Sánchez M, Maldonado Taillefer M, Gómez AM. Estudio con PET-FDG en paciente con antecedentes de leiomiosarcoma uterino durante la menstruación con resultado falso positivo. Rev Esp Med Nucl. 2005;24:205-6.
32. Kao CH. FDG uptake in a huge uterine myoma. Clin Nucl Med. 2003;3:249.
33. 18F]fluoro-2-deoxy-D-glucose in uterine leiomyoma: imaging of four patients by coincidence positron emission tomography. Nucl Med Commun. 2004;25:941-5.
34. Cherng SC, Liou CH, Fan YM, Yuan YN, Chiu CS. Intense FDG uptake of metastatic clear cell carcinoma from the ovary in a uterine leiomyoma. Clin Nucl Med. 2006;31:429-31.
35. Wahl RL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med. 2003;45:82S-95S.
36. Rodríguez Garrido M, Asensio del Barrio C, editores. PETTAC: Indicaciones, revisión sistemática y meta-análisis. Madrid: Agencia de Evaluación de Tecnologías Sanitarias - Instituto de Salud Carlos III - Ministerio de Sanidad y Consumo, 2004.
37. Von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405-22.